Monoamine oxidase inhibitors (MAOIs) were the first medications approved for the treatment of depression symptoms and are also used to treat several other medical conditions, such as Parkinson's ...

Prasinezumab, an experimental monoclonal antibody treatment, may help reduce the deterioration of motor skills in people with ...

These rapidly progressing subgroups were defined by the use of monoamine oxidase B (MAO-B) inhibitors at baseline, the ...

More research is needed to better understand how antidepressants work and their efficacy, especially when taken over the ...

Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO-B). Rasagiline demonstrates complete and selective ...

Although sauerkraut is perhaps the best-known national dish of Germany, and has been a staple of the German diet since the ...

Global Parkinson’s Disease Industry likely to raise at a CAGR of 5.1% and may surpass US$ 3.7 billion during forecast period ...

Study reveals ketamine's potent anti-inflammatory effects on neurological disorders, showing promise for treating major ...

A recent study in Nature Medicine evaluated the efficacy of prasinezumab, a monoclonal antibody, in slowing the progression ...

The FDA will close out April with five target action dates around indications that include pediatric seizures and a ...

a MAO-B = monoamine oxidase type B, MAO-A = monoamine oxidase type A. b Expressed as the molar concentration of drug required to inhibit enzyme activity by 50% (nmol/L). c Expressed as the ...